The BCR-ABL fusion gene, associated with the development of chronic myeloid leukemia (CML) [1-6], is the prototype of such a discovery and has ultimately led to the development of one of the first targeted molecular therapies in cancer [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.